Written questions by Dhesi.

What recent steps his Department has taken to support South Central Ambulance Service to meet target waiting times.

We acknowledge that urgent and emergency care performance has not consistently met expectations in recent years, and we are taking serious steps to address this.Our Urgent and Emergency Care Plan for 2025/26, backed by almost £450 million of capital investment, commits to reducing ambulance response times for Category 2 incidents to 30 minutes on average this year. We are also tackling unacceptable ambulance handover delays by introducing a maximum 45-minute standard, supporting ambulances to be released more quickly and get back on the road to treat patients.This commitment is supported by significant investment in upgrading hundreds of ambulances and expanding the capacity of urgent and emergency care services, enhancing both the speed and quality of care for patients in greatest need.The latest National Health Service performance figures, from October 2025, for South Central Ambulance Service which covers Slough, show that Category 2 incidents were responded to in 31 minutes 54 seconds on average, over six minutes faster than in October 2024.

What the current average waiting time is for an (a) ADHD and (b) autism assessment in (i) Slough constituency and (ii) the South East.

There is, at present, no single, established dataset that can be used to monitor waiting times for the assessment and diagnosis of attention deficit hyperactivity disorder (ADHD) for individual organisations or geographies in England. Although the data requested is not held centrally, it may be held locally by individual National Health Service trusts or commissioners.For the first time, NHS England published management information on ADHD waits at a national level on 29 May 2025, as part of its ADHD data improvement plan, and has also released technical guidance to integrated care boards (ICBs) to improve the recording of ADHD data, with a view to improving the quality of ADHD waits data and publishing more localised data in future. NHS England has also captured examples from ICBs who are trialling innovative ways of delivering ADHD services and is using this information to support systems to tackle ADHD waiting lists and provide support to address people’s needs.In respect of autism, the most recent data, published on 13 November 2025, is available on the NHS England website at the following link:https://digital.nhs.uk/data-and-information/publications/statistical/autism-statistics/october-2024-to-september-2025

What recent steps his Department has taken to ensure an adequate number of places are available for foundation year doctors moving onto speciality training posts.

As set out in our 10-Year Health Plan published on 3 July, we will work across the Government to prioritise United Kingdom medical graduates for foundation training, and to prioritise UK medical graduates and other doctors who have worked in the National Health Service for a significant period for specialty training. The plan also sets out that over the next three years we will create 1,000 new specialty training posts with a focus on specialties where there is the greatest need. We will set out next steps in due course.NHS England has also taken steps to tackle competition for speciality training places this year by changing General Medical Council registration requirements and limiting the number of applications that can be submitted by individuals.

What recent discussions he has had with integrated care boards on the steps they are taking to reduce waiting times for (a) ADHD and (b) autism assessments.

The Government has recognised that, nationally, demand for assessments for autism and attention deficit hyperactivity disorder (ADHD) has grown significantly in recent years and that people are experiencing severe delays for accessing such assessments. The Government’s 10-Year Health Plan will make the National Health Service fit for the future and recognises the need for early intervention and support.It is the responsibility of integrated care boards (ICBs) in England to make appropriate provision to meet the health and care needs of their local population, including providing access to autism and ADHD assessments, in line with relevant National Institute for Health and Care Excellence guidelines.The Medium-Term Planning Framework, published 24 October, was explicit that ICBs and providers are expected to optimise existing resources to reduce long waits for autism and ADHD assessments and improve the quality of assessments by implementing existing and new guidance, as published.In April 2023, NHS England published a national framework and operational guidance to help ICBs and the NHS to deliver improved outcomes for people referred to an autism assessment service. NHS England has continued to support services to identify challenges and how they might overcome these.  NHS England also established an ADHD taskforce to better understand the challenges affecting those with ADHD, including in accessing timely and equitable access to services and support. We are pleased that the final report was published on 6 November, and we are carefully considering its recommendations.

If he will make an assessment of the adequacy of waiting times at urgent care centres in Slough constituency.

No assessment has been made. The Department monitors urgent and emergency care performance nationally through NHS England, and the Urgent and Emergency Care Plan for 2025/26 sets commitments and improvement measures. This includes £250 million of capital funding to continue the expansion of co-located urgent treatment centres and same day emergency care to improve patient streaming and reduce overcrowding.NHS England works with local systems to implement these improvements and ensure patients receive timely and appropriate care.

What recent discussions he has had with integrated care boards on reducing waiting times for breast cancer treatment in Slough constituency.

The Government and the local integrated care board (ICB) has taken action to reduce waiting times for breast cancer treatment. This includes expansion of one-stop breast clinics and improved access to breast imaging. Action has also been taken to use enhanced digital triage to prioritise highest-risk cases. Moreover, targeted action has been taken to reduce the proportion of patients diagnosed at stage 3 or stage 4, with early signs of improvement in the timeliness of staging and biopsy results.Additionally, there are plans for extended-hours breast imaging sessions for Slough Community Diagnostic Centre after the scheduled opening in March 2026. Moreover, action has been taken across the local ICB to safeguard capacity for triple assessment and surgery. Participation in the national AI-enabled breast cancer early detection programme will help to support improved accuracy and faster reporting.

What recent steps his Department has taken to reduce the average diagnosis time for Postural Tachycardia Syndrome.

The Royal College of General Practitioners (RCGP) provides education on postural tachycardia syndrome (PoTS) through its Syncope Toolkit, which includes an e-learning module, a podcast and a webinar. These resources cover diagnosis and management and include patient perspectives to improve clinical understanding. The toolkit is available to GPs via the RCGP e-learning platform.As part of its Clinical Knowledge Summary (CKS) resources, the National Institute for Health and Care Excellence (NICE) has also published detailed guidance on the assessment and management of syncope and blackouts, which includes advice on PoTS. The purpose of CKSs is to provide primary care practitioners with quick, accessible, and evidence-based guidance on best practice for commonly occurring conditions.The guidance is available at the following link:https://cks.nice.org.uk/topics/blackouts-syncope/diagnosis/assessment/PoTS is diagnosed by a combination of GPs and specialist clinicians. GPs can diagnose PoTS in many cases but, if they are unsure of symptoms or if symptoms are complex, they will refer patients to specialists for diagnosis. The RCGP’s Syncope Toolkit provides diagnostic information to GPs, including the use of the active stand test, to rule out other conditions and potentially diagnose PoTS more quickly.Where patients are referred to secondary care for diagnosis, we are investing in additional capacity to deliver appointments to help bring waiting lists and times down. The Elective Reform Plan, published in January 2025, sets out the specific productivity and reform efforts needed to return to the constitutional standard, that 92% of patients to wait no longer than 18 weeks from Referral to Treatment, by March 2029.By expanding community-based services for routine monitoring and follow up, employing artificial intelligence for productivity and investing in digital tools and data, as outlined in the 10-Year Health Plan, we can ensure that consultants’ time is reserved for complex cases of PoTS, including specialist diagnostic assessments.While the Department recognises the significant challenges of PoTS diagnosis, responsibility for specific clinical pathways and specialist training rests with local NHS bodies.

What recent assessment he has made of the adequacy of the level of training provided to General Practitioners on (a) the treatment and (b) symptoms of Postural Tachycardia Syndrome .

The Royal College of General Practitioners (RCGP) provides education on postural tachycardia syndrome (PoTS) through its Syncope Toolkit, which includes an e-learning module, a podcast and a webinar. These resources cover diagnosis and management and include patient perspectives to improve clinical understanding. The toolkit is available to GPs via the RCGP e-learning platform.As part of its Clinical Knowledge Summary (CKS) resources, the National Institute for Health and Care Excellence (NICE) has also published detailed guidance on the assessment and management of syncope and blackouts, which includes advice on PoTS. The purpose of CKSs is to provide primary care practitioners with quick, accessible, and evidence-based guidance on best practice for commonly occurring conditions.The guidance is available at the following link:https://cks.nice.org.uk/topics/blackouts-syncope/diagnosis/assessment/PoTS is diagnosed by a combination of GPs and specialist clinicians. GPs can diagnose PoTS in many cases but, if they are unsure of symptoms or if symptoms are complex, they will refer patients to specialists for diagnosis. The RCGP’s Syncope Toolkit provides diagnostic information to GPs, including the use of the active stand test, to rule out other conditions and potentially diagnose PoTS more quickly.Where patients are referred to secondary care for diagnosis, we are investing in additional capacity to deliver appointments to help bring waiting lists and times down. The Elective Reform Plan, published in January 2025, sets out the specific productivity and reform efforts needed to return to the constitutional standard, that 92% of patients to wait no longer than 18 weeks from Referral to Treatment, by March 2029.By expanding community-based services for routine monitoring and follow up, employing artificial intelligence for productivity and investing in digital tools and data, as outlined in the 10-Year Health Plan, we can ensure that consultants’ time is reserved for complex cases of PoTS, including specialist diagnostic assessments.While the Department recognises the significant challenges of PoTS diagnosis, responsibility for specific clinical pathways and specialist training rests with local NHS bodies.

What recent assessment he has made of the availability of lactose free Olanzapine in (a) Slough and (b) Berkshire.

I have made no assessment of the availability of lactose free olanzapine in Slough and Berkshire. Information is not held at that level. However, I am informed by the Medicines and Healthcare products Regulatory Agency (MHRA) that records show that lactose free olanzapine should be readily available throughout the United Kingdom. At present there are 11 companies that do not list lactose as an ingredient in their olanzapine. All ingredients are listed on the relevant summary of product characteristics and should be confirmed by the healthcare professional prescribing the medicine and the pharmacist performing the dispensing.

What recent assessment his Department has made of the availability of treatment for those with Friedreich’s Ataxia.

Under the UK Rare Diseases Framework, the Government is working to improve access to specialist care, treatments, and drugs across all rare conditions. In February, we published the fourth England action plan reporting on progress.Following extensive consultation, NHS England has revised the national service specification for specialised neurology, which now includes an annex providing greater clarity for neurology sub-specialties. This includes the categories of both movement disorders and neurogenetics into which Friedreich’s Ataxia falls. Every specialised National Health Service neurology centre could and should see patients with Friedreich’s Ataxia.Although Skyclarys (omaveloxolone) is now licensed for those aged 16 years old and over, following an update from the company, Biogen, the National Institute for Health and Care Excellence (NICE) has had to terminate its appraisal of this medicine as the company has withdrawn its evidence submission. NICE will review its decision if the company decides to make a new submission. Further information is available at the following link:https://www.nice.org.uk/guidance/TA1061To avoid the possibility of creating a way to circumvent the appraisal process, NHS England is unable to fund medicines where companies have not engaged with NICE.

Pursuant to the Answer of 3 March 2025 to Question 35028 on LGBT Veterans Independent Review, what progress he has made on recommendations (a) 31, (b) 35, (c) 36, (d) 38 and (e) 42.

For recommendation 31, NHS England, in partnership with the Royal College of General Practitioners (GPs), continues to encourage participation in the Veteran Friendly GP accreditation scheme. To date, over 99% of primary care networks have at least one accredited GP in their area. For recommendation 35, since June 2025, 100% of National Health Service trusts have been accredited as ‘veteran aware’. This achievement, led by the Veterans Covenant Healthcare Alliance, reflects a national commitment to providing compassionate, personalised care to the Armed Forces Community.As for recommendations 36 and 38, I refer the Hon. Member to the answers I gave on 31 October 2025 to Questions 84296 and 84297.Finally, for recommendation 42, we recognise the importance of training for NHS staff on the needs of the Armed Forces Community. The NHS National Armed Forces Training and Education Programme will see NHS staff across England receiving dedicated training to help them identify and support patients with military backgrounds. This will be provided through a variety of channels: face to face; webinars; train the trainer; and e-learning. This launched in October 2025 and is supported by £1.8 million of investment over three years.

What recent assessment he has made of the adequacy of the availability of lactose-free medication in the South East.

The patient’s doctor is best placed to understand their requirements and might consider it necessary to prescribe lactose free products, possibly by brand. Alternatively, the doctor might be able to stipulate “lactose free” on the prescription and liaise with local pharmacists to find a suitable product.The British National Formulary is an evidence-based independent drug formulary used by health professionals as a source of key information on the selection, prescribing, dispensing, and administration of medicines. It advises that the lactose content in most medicines is too small to cause problems in most lactose-intolerant patients. However, in patients with severe lactose intolerance, lactose content should be determined before prescribing, especially if they are taking several products containing lactose.It is a requirement to state the presence of lactose on the label of a medicine. All ingredients present in a medicine must be declared in the patient information leaflet (PIL). The PIL is provided in the packaging of all medicines. In addition, the Medicines and Healthcare products Regulatory Agency and the electronic medicines compendium can be used to see the composition of medicines licensed in the United Kingdom, with further information available at the following link:https://www.medicines.org.uk/emc

What estimate he has made of the number of patients admitted to hospital with (a) covid, (b) flu and (c) respiratory syncytial virus in (i) 2025, (ii) 2024 and (iii) 2023.

NHS England publishes data on hospital admissions, including due to influenza and respiratory syncytial virus (RSV). The data is available at the following link:https://digital.nhs.uk/data-and-information/publications/statistical/hospital-accident--emergency-activityNHS England publishes data on hospital admissions including those that relate to the number of patients admitted with COVID-19. The data is available at the following link:https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/The following table shows the number of hospital admissions for COVID-19, influenza, and RSV in 2023/24 and 2024/25:Hospital Admissions2023/242024/25Influenza28,00359,320RSV19,57219,457COVID-1935,50723,507Source: NHS England Digital

Whether he has made an assessment of the potential merits of introducing a screening programme to detect undiagnosed heart defects in young people.

In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee (UK NSC), an independent scientific advisory committee which advises ministers and the National Health Service in all four countries on all aspects of population and targeted screening and which supports implementation.The UK NSC last reviewed screening for sudden cardiac death (SCD) in people under the age of 39 years old in 2019 and concluded that population screening should not be offered. Further information is available at the following link:https://view-health-screening-recommendations.service.gov.uk/sudden-cardiac-death/The UK NSC is currently examining the evidence for SCD screening and will open a public consultation to seek comments from members of the public and stakeholders on this in due course.

If he will ask the National Institute for Health and Care Excellence to respond to the coroner's Prevention of Future Death report following the death of Chloe Burgess.

The National Institute for Health and Care Excellence responded to the Hampshire Coroner’s Prevention of Future Death Report following the death of Chloe Burgess on 28 April 2025. The report is available at the following link:https://www.judiciary.uk/prevention-of-future-death-reports/chloe-burgess-prevention-of-future-deaths-report/

What progress he has made on implementing recommendation 36 of the LGBT Veterans Independent Review, published in May 2023.

Recommendation 36 relates to the expansion of the Veterans’ Covenant Healthcare Alliance (VCHA) accreditation scheme to include care homes and hospices. In July 2024, a pilot was launched by the Royal Star and Garter, supported by the VCHA. An evaluation of the pilot, led by the Royal British Legion, commenced in summer 2025. The evaluation findings will assess the practical viability of the scheme and will be accompanied by a full analysis of the options and associated financial costs.Recommendation 38 relates to treatment for addiction. Veterans can access all substance misuse services available to non-veterans. In addition, the National Health Service has commissioned Op COURAGE, the veterans’ mental health and wellbeing service which provides support to veterans with substance misuse and mental health issues. NHS England are developing plans to provide training and education about the needs of the Armed Forces community to NHS staff through the National Armed Forces training and education programme. This will include NHS services that provide support to veterans with addiction issues.

What progress he has made on implementing recommendation 38 of the LGBT Veterans Independent Review, published in May 2023.

Recommendation 36 relates to the expansion of the Veterans’ Covenant Healthcare Alliance (VCHA) accreditation scheme to include care homes and hospices. In July 2024, a pilot was launched by the Royal Star and Garter, supported by the VCHA. An evaluation of the pilot, led by the Royal British Legion, commenced in summer 2025. The evaluation findings will assess the practical viability of the scheme and will be accompanied by a full analysis of the options and associated financial costs.Recommendation 38 relates to treatment for addiction. Veterans can access all substance misuse services available to non-veterans. In addition, the National Health Service has commissioned Op COURAGE, the veterans’ mental health and wellbeing service which provides support to veterans with substance misuse and mental health issues. NHS England are developing plans to provide training and education about the needs of the Armed Forces community to NHS staff through the National Armed Forces training and education programme. This will include NHS services that provide support to veterans with addiction issues.

Whether he plans to include diagnosis targets for myeloma in the national cancer plan for England.

Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers such as myeloma, as early and quickly as possible, and to treat it faster, to improve outcomes.To tackle late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways.We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners.The National Cancer Plan will include further details on how we will improve outcomes for cancer patients, including speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates. Having consulted with key stakeholders and patient groups, the Plan will be published early in the new year.

What recent steps he has taken to help reduce the time taken to diagnose myeloma.

Information on the average time taken to diagnose myeloma in the South East is not held centrally. We publish 28-Day Faster Diagnosis data by suspected cancer, including provider and commissioner data, monthly. The latest publication is available at the following link:https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/monthly-data-and-summaries/2025-26-monthly-cancer-waiting-times-statistics/cancer-waiting-times-for-august-2025-26-provisional/We recognise that there is more to be done to ensure that patients have timely access to diagnosis, and we remain committed to diagnosing all cancer types earlier, including myeloma. To tackle late diagnoses, the National Health Service is implementing non-specific symptom (NSS) pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. There are currently 115 NSS services operating in England, ensuring more patients benefit from quicker access to the right investigations.

What recent estimate he has made of the average time taken to diagnose myeloma in the South East.

Information on the average time taken to diagnose myeloma in the South East is not held centrally. We publish 28-Day Faster Diagnosis data by suspected cancer, including provider and commissioner data, monthly. The latest publication is available at the following link:https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/monthly-data-and-summaries/2025-26-monthly-cancer-waiting-times-statistics/cancer-waiting-times-for-august-2025-26-provisional/We recognise that there is more to be done to ensure that patients have timely access to diagnosis, and we remain committed to diagnosing all cancer types earlier, including myeloma. To tackle late diagnoses, the National Health Service is implementing non-specific symptom (NSS) pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. There are currently 115 NSS services operating in England, ensuring more patients benefit from quicker access to the right investigations.